Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
about
Vitamin D: link between osteoporosis, obesity, and diabetes?Phosphate control in end-stage renal disease: barriers and opportunitiesCalcium-sensing receptor 20 years laterVitamin D in renal transplantation - from biological mechanisms to clinical benefitsCinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysisA critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument.Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis.Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.Phosphate binders in chronic kidney disease: a systematic review of recent data.Care of undocumented-uninsured immigrants in a large urban dialysis unit.Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients.Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.A physiologic-based approach to the evaluation of a patient with hyperphosphatemiaVelcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjectsVitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.Circulatory mitochondrial DNA is a pro-inflammatory agent in maintenance hemodialysis patients.Vitamin D deficiency in children with a chronic illness-seasonal and age-related variations in serum 25-hydroxy Vitamin D concentrations.Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends.Healthcare use and costs before and after parathyroidectomy in patients on dialysis.Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study.Maxillofacial brown tumors in secondary hyperparathyroidism: A case report and literature review.Impact of the uremic milieu on the osteogenic potential of mesenchymal stem cells.The induction of C/EBPβ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney diseaseBone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease.Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism.Uncorrected and Albumin-Corrected Calcium, Phosphorus, and Mortality in Patients Undergoing Maintenance DialysisDynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design.Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriolComparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D studySequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial.A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgeryDysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes.Diagnostic Accuracy Study of Intraoperative and Perioperative Serum Intact PTH Level for Successful Parathyroidectomy in 501 Secondary Hyperparathyroidism Patients.Association of Increased Serum Leptin with Ameliorated Anemia and Malnutrition in Stage 5 Chronic Kidney Disease Patients after Parathyroidectomy
P2860
Q26828851-5465E90D-B937-4DB7-9220-1E3015A85DD4Q26853372-512B17D7-4FC8-4F92-8886-E3E02E0D7C9DQ26862683-52E80359-32E7-4E17-9AE9-F1FB28726307Q27026932-6C57B99A-2F41-4756-9365-C66ED50351BFQ28079300-2DF49BFE-0A60-42BC-AB0C-6422193A110AQ30241974-6D2A27CD-B18D-4C08-8D1F-0819A3ACC215Q30250264-944A6DAD-4C36-488A-9D2F-C59E63E6F44CQ30251450-6B64ECF5-C8CC-46AE-B232-4B150EC9DCC3Q30524139-2899B378-D14D-4B39-875A-A7C62DE7D7C1Q31039292-AC16D8BF-E50A-440F-8262-15D641BE07DCQ31095229-B02296C9-4AD9-425F-ABE2-0CD2461540E0Q33625482-260F3D94-8E7C-4A83-9215-E75B845366DBQ33703957-EB8629C4-F8FA-4910-9D30-AD8E15DB97A5Q33894092-2487C30B-ECDE-477D-AE2E-7589297FB6E7Q34385273-AC85BFA0-586C-4DEC-A1B4-681910AB6115Q34621641-F104FA03-6674-45D9-AE16-C6329FCD4456Q34653708-CA439BC3-5D70-4979-BE24-727EE99B850AQ34667855-11914076-4661-4C05-BA1C-4BA2C2FE2B35Q34704916-0E315CC5-842D-4560-9534-E2487252B392Q34790266-B22E0EF3-274E-4404-AF58-A9612ADFEBC4Q34990456-C4414A3A-83F7-4C7A-9C12-179195BB7CA0Q35025291-6CA749DD-D306-4AD8-AAA2-A44C3662DA84Q35032235-82D2D557-3656-4CAD-AF38-EF68AF7643F1Q35119028-D553410A-07E2-479B-8597-ACBA92B29AAAQ35245052-5115EA85-633C-4EF8-A681-CEF058D381D2Q35614174-19A54A3E-44FF-4C38-9AEA-62FA7C0C89B2Q35658726-F7523BFB-B8A7-45A5-B60A-9A65149D4E09Q35790561-25D0CE81-4041-48AC-B4EB-B33B3D646D05Q35824855-5413E878-6015-4F20-A02B-E8279514DC9BQ35917442-F523F5C8-280B-428A-BC88-C5BC2DD0700BQ36045060-64523FA7-A8D1-439D-BB25-3E99D72BF286Q36121519-0FD15A2C-22E7-48A8-B010-5DC0156DB161Q36199558-1C078560-0066-4083-9394-AFD7B23420A7Q36248860-1A608138-A15A-4D04-9E3B-66C1C4D41A1FQ36381365-8E5C8389-39FA-426A-A53F-00D45D9071EDQ36432849-8EBA0BF4-D7DC-458A-8477-F981FDF65419Q36711992-8AFE08FB-D863-4D4B-B234-3367D41D670FQ36941143-EDBFEC44-F409-4A65-88E6-A8BD20FA3BB6Q36941547-DCF5B134-CFAB-4F09-A346-D42B213084ABQ37010415-82F4447E-7FE3-4D60-8E37-41CFB8618E40
P2860
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Secondary hyperparathyroidism: ...... sion, and therapeutic options.
@en
Secondary hyperparathyroidism: ...... sion, and therapeutic options.
@nl
type
label
Secondary hyperparathyroidism: ...... sion, and therapeutic options.
@en
Secondary hyperparathyroidism: ...... sion, and therapeutic options.
@nl
prefLabel
Secondary hyperparathyroidism: ...... sion, and therapeutic options.
@en
Secondary hyperparathyroidism: ...... sion, and therapeutic options.
@nl
P356
P1476
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options
@en
P2093
Francesco Locatelli
John Cunningham
P304
P356
10.2215/CJN.06040710
P577
2011-03-31T00:00:00Z